X4 Pharmaceuticals (XFOR) Shares Outstanding (Weighted Average) (2017 - 2025)

X4 Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $42.3 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 531.04% year-over-year to $42.3 million; the trailing twelve-month figure through Dec 2025 stood at $42.3 million (up 531.04% YoY), and the FY2025 full-year result was $42.3 million, up 531.04% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $42.3 million, down from $43.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $170.8 million in Q3 2023, with the low at $3.7 million in Q4 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $41.4 million across 5 years, with a median of $23.6 million in 2021.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) tumbled 96.08% — and 2025, when it jumped 546.3%.
• X4 Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $13.3 million in 2021, then tumbled by 71.87% to $3.7 million in 2022, then surged by 58.94% to $5.9 million in 2023, then grew by 13.08% to $6.7 million in 2024, then surged by 531.04% to $42.3 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $42.3 million (Q4 2025), $43.3 million (Q3 2025), and $7.4 million (Q2 2025), per Business Quant data.